Keisuke Anan

Keisuke Anan

Auto-generated profile, based on publicly available information

Keisuke Anan

Department of Healthcare Epidemiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2017 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
KKKodai Kawamura
Kodai Kawamura
KIKazuya Ichikado
Kazuya Ichikado
YYYuko Yasuda
Yuko Yasuda
KAKeisuke Anan
Keisuke Anan
MSMoritaka Suga
Moritaka Suga
Acute exacerbation (AE) of idiopathic pulmonary fibrosis (IPF) is a fatal condition without an established pharmaceutical treatment. Most patients are treated with high-dose corticosteroids and broad-spectrum antibiotics. Azithromycin is a macrolide with immunomodulatory activity and may be beneficial for treatment of acute lung injury. The objective of this study was to determine the effect of azithromycin on survival of patients with idiopathic AE of IPF. We evaluated 85 consecutive patients hospitalized in our department for idiopathic AE of IPF from April 2005 to August 2016. The initial 47 patients were treated with a fluoroquinolone-based regimen (control group), and the following 38 consecutive patients were treated with azithromycin (500 mg/day) for 5 days. Idiopathic AE of IPF was defined using the criteria established by the 2016 International Working Group. Mortality in patients treated with azithromycin was significantly lower than in those treated with fluoroquinolones (azithromycin, 26% vs. control, 70%; p < 0.001). Multivariate analysis revealed that the two variables were independently correlated with 60-day mortality as determined by the Acute Physiology and Chronic Health Evaluation II score (p = 0.002) and azithromycin use (p < 0.001). Azithromycin may improve survival in patients with idiopathic AE of IPF.

28 July 2016 in SpringerPlus
Verified
Journal Article
Open access
PDF file
KKKodai Kawamura
Kodai Kawamura
KIKazuya Ichikado
Kazuya Ichikado
MTMakoto Takaki
Makoto Takaki
YSYoshihiko Sakata
Yoshihiko Sakata
YYYuko Yasuda
Yuko Yasuda
MSMoritaka Suga
Moritaka Suga
Acute respiratory distress syndrome is a life-threatening form of respiratory failure without an established pharmacological treatment. Recently, macrolides have been found to be beneficial in cases of acute lung injury, but evidence is limited. This single-centre retrospective cohort evaluation of hospitalized patients with sepsis-associated acute respiratory distress syndrome aimed to assess the impact of azithromycin on clinical outcomes by using a propensity score analysis. All data were collected prospectively as part of ongoing research on high-resolution computed tomography of acute respiratory distress syndrome. The primary outcome was 60-day mortality; the secondary outcome was the number of ventilator-free days. Twenty-nine of 125 patients with sepsis-associated acute respiratory distress syndrome (23.2 %) received azithromycin within 24 h after acute respiratory distress syndrome diagnosis. After adjusting for potentially confounding covariates, azithromycin use was associated with lower 60-day mortality (hazard ratio, 0.31; 95 % confidence interval, 0.11–082; P = 0.02) and a shorter time to successful discontinuation of mechanical ventilation. Azithromycin use was associated with decreased mortality and ventilator dependency in patients with sepsis-associated acute respiratory distress syndrome. Further well-designed prospective studies are needed.

25 June 2019 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
KKKodai Kawamura
Kodai Kawamura
KIKazuya Ichikado
Kazuya Ichikado
HIHidenori Ichiyasu
Hidenori Ichiyasu
KAKeisuke Anan
Keisuke Anan
YYYuko Yasuda
Yuko Yasuda
TSTakuro Sakagami
Takuro Sakagami
Here, we present real-world data on the incidence and risk factors of acute exacerbation (AE) in patients with chronic fibrotic interstitial pneumonia (CFIP) treated with antifibrotic agents, which has been previously poorly documented. We retrospectively examined clinical characteristics, incidence and risk factors of AE in a cohort of 100 patients with CFIP (n = 75, idiopathic pulmonary fibrosis [IPF]; n = 25, other conditions), all of whom received antifibrotic agents in a real-world setting. The median follow-up was 17.4 months (interquartile range [IQR], 6.6 to 26.7 months). During the follow-up periods, 21 patients experienced AE after starting antifibrotic agents. The estimated 1-, 2-, and 3-year AE incidence rates were 11.4% (95% confidence interval [95%CI], 6.2–20.3%), 32% (95%CI, 20.7–47.4%), and 36.3% (95%CI 23.5–53.1%), respectively. Decreased baseline lung function (forced vital capacity and carbon monoxide diffusing capacity of the lung), existence of pulmonary hypertension estimated from an echocardiogram, higher Interstitial Lung Disease-Gender, Age, and Physiology (ILD-GAP) score, supplementary oxygen, and concomitant corticosteroid and proton-pump inhibitor (PPI) use upon starting the antifibrotic agent were risk factors of AE. Concomitant corticosteroid and PPI use and corticosteroid dose were risk factor of AE in a multivariate Cox regression hazard model adjusting for ILD-GAP score. AE of CFIP is more common in patients with physiologically and functionally advanced disease under antifibrotic agents. Prudent use of corticosteroids and PPIs when initiating antifibrotic agents may be recommended. Further studies are warranted.

16 February 2021 in Mycoses
Verified
Journal Article
Closed access
PDF file
KAKeisuke Anan
Keisuke Anan
Yuki KataokaYuki Kataoka
Yuki Kataoka
SOShinji Okabayashi
Shinji Okabayashi
RYRyohei Yamamoto
Ryohei Yamamoto
HNHo Namkoong
Ho Namkoong
YYYosuke Yamamoto
Yosuke Yamamoto

1 January 2022 in Respiratory Investigation
Verified
Journal Article
Closed access
KAKeisuke Anan
Keisuke Anan
YOYoshiyasu Oshima
Yoshiyasu Oshima
TOTakayuki Ogura
Takayuki Ogura
YTYuko Tanabe
Yuko Tanabe
AHAkiko Higashi
Akiko Higashi
YOYOHEI OKADA
YOHEI OKADA

1 October 2018 in Journal of Thoracic Disease
Verified
Journal Article
Closed access
PDF file
KAKeisuke Anan
Keisuke Anan
KKKodai Kawamura
Kodai Kawamura
MSMoritaka Suga
Moritaka Suga
KIKazuya Ichikado
Kazuya Ichikado
Background: Although acute respiratory distress syndrome (ARDS) reportedly shows various clinical phenotypes with different risk and prognostic factors, few studies have assessed the clinical features and prognosis of pulmonary and extrapulmonary ARDS. The aim of the present study was to investigate clinical differences between pulmonary and extrapulmonary ARDS. Methods: In total, 200 patients who met the Berlin criteria and were diagnosed with ARDS between October 2004 and September 2017 were included. We classified the patients into pulmonary and extrapulmonary ARDS groups. Both groups were assessed for 60-day mortality, duration of ventilation, and other clinical features. Results: There were 150 and 50 patients in the pulmonary and extrapulmonary ARDS groups, respectively. The two groups showed no significant differences in any assessment parameters except the serum lactate dehydrogenase (LDH) level, which was higher in the extrapulmonary ARDS group (P=0.01). After adjustment for potentially confounding covariates, there were no significant differences in 60-day mortality (P=0.99) and the duration of ventilation (P=0.45) between the two groups. Mortality was significantly associated with the disseminated intravascular coagulation (DIC) score, high-resolution computed tomography (HRCT) score, and serum LDH level in the pulmonary ARDS group and the DIC score and HRCT score in the extrapulmonary ARDS group. Conclusions: Pulmonary and extrapulmonary ARDS may be comparable in terms of the prognosis and duration of ventilation. DIC and HRCT scores may be common clinical predictors of mortality with ARDS.